O
12.43
0.97 (8.46%)
| Penutupan Terdahulu | 11.46 |
| Buka | 11.48 |
| Jumlah Dagangan | 5,768,896 |
| Purata Dagangan (3B) | 2,831,947 |
| Modal Pasaran | 2,648,180,224 |
| Harga / Jualan (P/S) | 35.65 |
| Harga / Buku (P/B) | 7.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -597.47% |
| EPS Cair (TTM) | -1.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -27.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.66% |
| Nisbah Semasa (MRQ) | 10.22 |
| Aliran Tunai Operasi (OCF TTM) | -145.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -87.96 M |
| Pulangan Atas Aset (ROA TTM) | -27.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ocular Therapeutix, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.40 |
|
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.82% |
| % Dimiliki oleh Institusi | 87.01% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2025 | 13,161,462 |
| Summer Road Llc | 30 Sep 2025 | 12,579,657 |
| Deep Track Capital, Lp | 30 Sep 2025 | 11,932,137 |
| Avoro Capital Advisors Llc | 30 Sep 2025 | 10,250,000 |
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 3,497,307 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 31.00 (Piper Sandler, 149.40%) | Beli |
| Median | 21.00 (68.95%) | |
| Rendah | 19.00 (HC Wainwright & Co., 52.86%) | Beli |
| Purata | 23.43 (88.50%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 11.38 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Nov 2025 | 19.00 (52.86%) | Beli | 12.13 |
| 08 Oct 2025 | 19.00 (52.86%) | Beli | 11.91 | |
| Chardan Capital | 05 Nov 2025 | 21.00 (68.95%) | Beli | 10.81 |
| 02 Oct 2025 | 21.00 (68.95%) | Beli | 11.06 | |
| TD Cowen | 30 Oct 2025 | 20.00 (60.90%) | Beli | 11.82 |
| Baird | 03 Oct 2025 | 24.00 (93.08%) | Beli | 11.41 |
| Piper Sandler | 03 Oct 2025 | 31.00 (149.40%) | Beli | 11.41 |
| JMP Securities | 01 Oct 2025 | 29.00 (133.31%) | Beli | 11.04 |
| Needham | 01 Oct 2025 | 20.00 (60.90%) | Beli | 11.04 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DUGEL PRAVIN | 12.14 | 12.12 | -19,530 | -236,313 |
| HEIER JEFFREY S. | - | 12.10 | -3,469 | -41,975 |
| KAISER PETER | - | 12.10 | -3,007 | -36,385 |
| NAYAK SANJAY | - | 12.10 | -1,878 | -22,724 |
| Jumlah Keseluruhan Kuantiti Bersih | -27,884 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -337,396 | |||
| Purata Pembelian Keseluruhan ($) | 12.14 | |||
| Purata Jualan Keseluruhan ($) | 12.11 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DUGEL PRAVIN | Pegawai | 26 Nov 2025 | Dibuang (-) | 49,754 | 12.14 | 604,014 |
| DUGEL PRAVIN | Pegawai | 26 Nov 2025 | Diperolehi (+) | 49,754 | 12.14 | 604,014 |
| HEIER JEFFREY S. | Pegawai | 24 Nov 2025 | Jual (-) | 3,469 | 12.10 | 41,975 |
| KAISER PETER | Pegawai | 24 Nov 2025 | Jual (-) | 3,007 | 12.10 | 36,385 |
| DUGEL PRAVIN | Pegawai | 24 Nov 2025 | Jual (-) | 19,530 | 12.10 | 236,313 |
| NAYAK SANJAY | Pegawai | 24 Nov 2025 | Jual (-) | 1,878 | 12.10 | 22,724 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |